Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (ABVX) EBIT (2022 - 2025)

Historic EBIT for Abivax (ABVX) over the last 2 years, with Q3 2025 value amounting to -$94.4 million.

  • Abivax's EBIT fell 7118.88% to -$94.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$242.4 million, marking a year-over-year change of. This contributed to the annual value of -$184.8 million for FY2024, which is 3415.84% down from last year.
  • Per Abivax's latest filing, its EBIT stood at -$94.4 million for Q3 2025, which was down 7118.88% from -$52.6 million recorded in Q2 2025.
  • Abivax's 5-year EBIT high stood at -$38.0 million for Q2 2024, and its period low was -$94.4 million during Q3 2025.